PAR - 416 mill MC
RAC - 423 mill MC
OPT - 456 mill MC
NEU - 260 mill MC
IXC - 49 mill MC
Even if it got to NEU say, thats 5 x from here or $3.50 share price. Get real punters, this is the biggest gift on the ASX. Wait in 2 years time when we will say to ourselves, I cant believe how obvious this was, wish I bought more.
Dr Duthy also noted that comparable companies on the ASX which are either repurposing approved therapies, developing orphan drugs, or developing ophthalmology therapies, such asParadigm Biopharmaceuticals (ASX: PAR),Opthea (ASX: OPT),Race Oncology (ASX: RAC)orNeuren Pharmaceuticals (ASX: NEU), are priced significantly higher despite similar stages of development.
Patience people patience
Ann: Invex Granted Key European Patent for Exenatide, page-45
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49049 | 8.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 15296 | 1 |
View Market Depth
| Last trade - 10.00am 04/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable